Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02554214
Other study ID # 1007
Secondary ID
Status Recruiting
Phase N/A
First received September 10, 2015
Last updated September 17, 2015
Start date September 2015

Study information

Verified date September 2015
Source Rheon Medical SA
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.

The objectives of the study are to verify the performance and safety of the Glafkos adjustable glaucoma drainage device system. Performance will be measured assessing the possibility to adjust the intra-ocular pressure post-operatively. Safety will be measured by the incidence and severity of adverse events.

The Glafkos device will be implanted in combination with a seton tube. The implant is placed under a scleral flap, in a manner analogous to the ex-Press device (Alcon). The distal end of the draining tube is linked to a seton draining tube, which is linked to a plate placed under the extraocular muscles, creating a filtering space at the orbit (filtering bleb).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient must be 18 years of age or older.

2. Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory glaucoma after failed previous filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.

3. Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.

4. Patient condition is indicated for primary and secondary filtration surgery.

5. Presence of ocular hypertension defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.

6. Distance Snellen best corrected visual acuity (BCVA) better than 0.6 in the fellow eye.

7. For the first three subjects the Snellen BCVA in the study eye should be 0.5 or less. In addition, the visual field defined by the Mean Defect (MD) shall be higher than 10 dB.

8. Optic neuropathy is exclusively attributed to glaucoma.

9. Patient agreed to sign the written inform consent prior to entering into the investigation.

10. Patient is able and willing to complete post-operative follow-up requirements.

Exclusion Criteria:

1. Diagnosis of neovascular glaucoma, congenital glaucoma.

2. History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.

3. Proliferative or severe non-proliferative retinopathy in either eye.

4. Congenital anomaly of the anterior chamber angle in the study eye.

5. Optic neuropathy other than glaucoma in the study eye.

6. Patient with retinal vein occlusion in the study eye.

7. Patient with retinal artery occlusion in the study eye.

8. Patient with corneal opacifications or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.

9. Patient with a history of severe eye trauma in the study eye.

10. Patient with ocular malformations such as microphthalmia in the study eye.

11. Patient with concurrent inflammatory/infective eye disorder in the study eye.

12. Patient with any sign of past or present uveitis (anterior/posterior).

13. Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.

14. Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.

15. Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
Glafkos drainage device


Locations

Country Name City State
Switzerland Montchoisi Clinic Lausanne Vaud

Sponsors (1)

Lead Sponsor Collaborator
Rheon Medical SA

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and type of SADE per patient. 24 months Yes
Primary IOP measurement IOP reduced by = 20% or IOP < 21 mmHg, and no IOP < 5 mmHg on two consecutive visits after 3 months. 24 months No
Secondary Comprehensive biomicroscopy examination Anterior and posterior segments examination using a slit-lamp biomicroscope to evaluate the condition of the cornea (epithelium, stroma, endothelium), the anterior chamber, the iris, the lens, the irido-corneal angle (cf. gonioscopy outcome 9), the vitreous body, retinal and optic nerve anatomy (cf funduscopy outcome 7). day 1, day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24 Yes
Secondary Assessment of easiness of surgery by surgeon scale: 0=very easy to 5=very difficult day 0 No
Secondary Assessment of easiness of adjustment scale: 0=very easy to 5=very difficult for 24 months No
Secondary Subjective refraction Assessment of the subjective refraction based on trial and error asking using trial lenses to achieve the best corrected visual acuity day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24 No
Secondary Funduscopy evaluation indirect funduscopy using a 90D lens to evaluate the optic nerve anatomy (cup to disk ratio measurement) and the retinal structures day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24 No
Secondary Snellen BCVA Distance (6m) decimal visual acuity after best optical correction was provided day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24 No
Secondary gonioscopy assessment Irido-corneal angle assessment using the Schaffer grading scale (1-4) day 7 and day 28 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A